Role of transforming growth factor-beta(2) in, and a possible Transforming Growth Factor-beta(2) gene polymorphism as a marker of, renal dysfunction in essential hypertension: A study in Turkish patients

Basit Öğe Kaydı
dc.contributor.authorBahçebaşı, Zerrin Bicik
dc.contributor.authorGönen, Sevim
dc.contributor.authorBahçebaşı, Talat
dc.contributor.authorReis, Kadriye
dc.contributor.authorArınsoy, Turgay
dc.contributor.authorSindel, Şükrü
dc.date.accessioned2020-04-30T23:31:44Z
dc.date.available2020-04-30T23:31:44Z
dc.date.issued2005
dc.departmentDÜ, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.descriptionWOS: 000231920000002en_US
dc.descriptionPubMed: 24672129en_US
dc.description.abstractBackground: Many studies have shown that transforming growth factor (TGF)-beta has a major role in renal scarring in many renal diseases and hypertension. Objectives: The primary aim of this study was to investigate both the relationship between hypertension and serum and urinary levels of TGF-beta(2) (a more sensitive isoform for glomeruli than TGF-beta(1))), and the effects of combination therapy with perindopril + indapamide on microalbuminuria, which becomes an early indicator of hypertensive benign nephropathy, and serum and urinary TGF-beta(2) levels in patients with mild to moderate essential hypertension. In addition, we examined the possible relationship between TGF-beta(2) gene polymorphism and essential hypertension. Methods: This study was conducted at the Department of Nephrology, Medical Faculty, Gazi University, Ankara, Turkey. Patients aged >= 18 years with newly diagnosed mild to moderate essential hypertension (systolic/diastolic blood pressure [SBP/DBP] > 120/> 80 mm Hg) who had not previously received antihypertensive treatment were included in the study. Patients with stage I hypertension received perindopril 2 mg + indapamide 0.625 mg (tablet), and patients with stage 11 hypertension received perindopril 4 mg + indapamide 1.125 mg (tablet). All study drugs were given OD (morning) PO with food for 6 months. Serum and urinary TGF-beta(2) and creatinine levels and serum and urinary albumin levels were measured before and after perindopril + indapamide administration. Amplified DNA fragments of the TGF-beta(2) primer region were screened using amplification refractory mutation system polymerase chain reaction analysis, and the number of ACA repeats was confirmed by DNA sequencing. Genetic studies were performed using a commercial TGF-beta(2) kit. Results: Forty patients were enrolled in the study, and 38 patients (27 women, 11 men; mean [SD] age, 46.3 [6.5] years) completed it. SBP and DBP were significantly decreased from baseline with perindopril/indapamide (both, P < 0.001). Microalbuminuria and urinary TGF-beta(2) levels also decreased significantly from baseline (P = 0.04 and P < 0.001, respectively), whereas the serum TGF-beta(2) level did not change significantly. Three patients, all of whom were found to have TGF-beta(2) gene mutations, had increased urinary TGF-beta(2) levels despite good blood pressure control. Conclusions: The results of this study in patients with mild to moderate hypertension suggest that, despite good clinical control of blood pressure, the persistence of microalbuminuria and high urinary TGF-beta(2) levels might predict renal impairment. When treating these patients, genetic tendencies and possible polymorphisms on the TGF-beta(2) locus should be kept in mind.en_US
dc.identifier.doi10.1016/j.curtheres.2005.08.003en_US
dc.identifier.endpage278en_US
dc.identifier.issn0011-393X
dc.identifier.issn1879-0313
dc.identifier.issue4en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage266en_US
dc.identifier.urihttps://doi.org/10.1016/j.curtheres.2005.08.003
dc.identifier.urihttps://hdl.handle.net/20.500.12684/4443
dc.identifier.volume66en_US
dc.identifier.wosWOS:000231920000002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofCurrent Therapeutic Research-Clinical And Experimentalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjecthypertensionen_US
dc.subjectperindoprilen_US
dc.subjectindapamideen_US
dc.subjectmicroalbuminuriaen_US
dc.subjectTGF-beta(2)en_US
dc.subjectgene polymorphismen_US
dc.titleRole of transforming growth factor-beta(2) in, and a possible Transforming Growth Factor-beta(2) gene polymorphism as a marker of, renal dysfunction in essential hypertension: A study in Turkish patientsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
4443.pdf
Boyut:
726.99 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu